TMS Center of Colorado First in Denver Area to Offer New FDA-Cleared Treatment for Obsessive-Compulsive Disorder (OCD) in Adults

Denver-area patients have access to first-ever, non-invasive, non-drug medical device for treatment of OCD using Brainsway Deep TMS™

DENVER –TMS Center of Colorado is the first in the region and one of the first in the nation to offer a new non-drug treatment for obsessive-compulsive disorder (OCD) in adults using the Brainsway Deep Transcranial Magnetic Stimulation System (Deep TMS®). OCD is the second FDA indication granted for Brainsway Deep TMS, which was cleared in 2013 for the treatment of major depressive disorder (MDD).

“We have long known about the benefits of Deep TMS therapy for psychiatric disorders other than depression,” said TMS Center of Colorado Medical Director Ted Wirecki, M.D. “FDA clearance now provides an additional treatment option for those suffering from OCD, which mental health professionals know is a very challenging disorder to treat”.

TMS Center of Colorado was the first center in Colorado to offer Brainsway Deep TMS therapy, which has helped tens of thousands of patients in successfully treating depression.

More than two million adults in the United States suffer from obsessive-compulsive disorder (OCD), which is characterized by a pattern of obsessive thoughts and compulsive, repetitive behaviors. For many, treatment with antidepressant medications delivered at very high doses is able to control the disorder. However, up to 40 percent1 of those suffering from OCD are considered treatment-resistant, which means that they are not, or are no longer, responding to first-line treatment with medication or psychotherapy.

In August, the FDA cleared Brainsway Deep TMS for OCD, a major milestone for individuals suffering from this disorder. The clearance was based on a study conducted in 11 medical centers in the United States, Canada and Israel. The study included only patients who were treatment-resistant and included twenty-minute Deep TMS sessions conducted five times per week over a six-week period. More than half of those in the active group achieved a 20 percent or greater reduction in symptom severity.

The Brainsway Deep TMS used at TMS Center of Colorado differs from other TMS devices because it can directly stimulate areas of the brain at a greater depth and breadth safely and efficiently. One such area is the anterior cingulate gyrus, a region known for many years to be directly involved in OCD. A special coil was developed to target this area – versus the lateral pre-frontal cortex targeted in treating depression – and as a result, the Deep TMS device is the only TMS system on the market cleared for OCD treatment.

Not all insurance companies cover OCD treatment with Deep TMS, but the FDA clearance is expected to pave the way for widespread coverage, as it did with major depressive disorder (MDD).

“Ninety percent of MDD patients are now eligible for coverage through private or government insurance, and we expect the same to happen with treatment-resistant OCD patients,” added Dr. Wirecki.


  1. Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry. 2006;11(9):805-814.